Topic: Cancer treatment

Professor Robert Baxter and his team have tested a promising new therapy, which can effectively block the growth of triple negative breast cancer by inhibiting two proteins that act as stimulators.

This research has provided a groundbreaking insight into the relationship between the protein dyskerin
and neuroblastoma, a deadly childhood cancer.

The aim of this 5 year program is to increase survival rates of children with Acute Lymphoblastic Leukaemia (ALL) and ultimately develop prevention strategies.